Janux Therapeutics Inc (JANX)
$46.5
Performance
- $45.95$49.74$46.50
1.18%
Downside
Day's Volatility :7.62%
Upside
6.51%
- $7.79$65.60$46.50
83.25%
Downside
52 Weeks Volatility :88.13%
Upside
29.12%
Returns
| Period | Janux Therapeutics Inc | Sector (Health Care) | Index (Russel 2000) |
|---|---|---|---|
3 Months | 5.2% | -6.9% | 0.0% |
6 Months | 2.54% | -1.7% | 0.0% |
1 Year | 410.43% | 10.4% | 0.0% |
3 Years | 154.93% | 8.8% | -24.1% |
Highlights
Market Capitalization | 2.6B |
Book Value | $12.54 |
Earnings Per Share (EPS) | -1.17 |
Wall Street Target Price | 66.182 |
Profit Margin | 0.0% |
Operating Margin TTM | -8164.46% |
Return On Assets TTM | -9.93% |
Return On Equity TTM | -12.05% |
Revenue TTM | 13.0M |
Revenue Per Share TTM | 0.26 |
Quarterly Revenue Growth YOY | -82.6% |
Gross Profit TTM | -44.8M |
EBITDA | -83.9M |
Diluted Eps TTM | -1.17 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -1.25 |
EPS Estimate Next Year | -1.78 |
EPS Estimate Current Quarter | -0.33 |
EPS Estimate Next Quarter | -0.38 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 42.33%
Technicals Summary
Sell
Neutral
Buy
Janux Therapeutics Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Janux Therapeutics Inc | -11.93% | 2.54% | 410.43% | 154.93% | 67.33% |
 Regeneron Pharmaceuticals, Inc. | -22.64% | -24.32% | -6.91% | 15.67% | 106.43% |
 Biontech Se | -2.39% | 5.8% | 10.48% | -66.36% | 407.41% |
 Alnylam Pharmaceuticals, Inc. | -16.76% | 63.55% | 51.52% | 31.97% | 130.85% |
 Vertex Pharmaceuticals Incorporated | -5.17% | 0.63% | 27.5% | 148.14% | 106.59% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Janux Therapeutics Inc | NA | NA | NA | -1.25 | -0.12 | -0.1 | NA | 12.54 |
Regeneron Pharmaceuticals, Inc. | 18.38 | 18.38 | 1.11 | 44.91 | 0.17 | 0.07 | NA | 272.04 |
Biontech Se | 160.8 | NA | 0.04 | -3.04 | -0.02 | -0.01 | NA | 79.73 |
Alnylam Pharmaceuticals, Inc. | NA | NA | -0.49 | -0.17 | -15.01 | -0.03 | NA | 0.25 |
Vertex Pharmaceuticals Incorporated | 32.84 | NA | 1.18 | 0.54 | -0.03 | 0.12 | NA | 60.65 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Janux Therapeutics Inc | Buy | $2.6B | 67.33% | NA | 0.0% |
Regeneron Pharmaceuticals, Inc. | Buy | $81.7B | 106.43% | 18.38 | 33.61% |
Biontech Se | Buy | $24.5B | 407.41% | 160.8 | -15.36% |
Alnylam Pharmaceuticals, Inc. | Buy | $32.1B | 130.85% | NA | -15.86% |
Vertex Pharmaceuticals Incorporated | Buy | $116.2B | 106.59% | 32.84 | -4.51% |
Insights on Janux Therapeutics Inc
Decreasing Revenue
Revenue is down for the last 2 quarters, 8.89M → 439.0K (in $), with an average decrease of 95.1% per quarter
Decreasing Net Profit
Netprofit is down for the last 2 quarters, -5.95M → -28.05M (in $), with an average decrease of 370.9% per quarter
Institutional Holdings
RA Capital Management, LLC
17.51%FMR Inc
14.95%Orbimed Advisors, LLC
5.69%Paradigm Biocapital Advisors LP
4.59%BlackRock Inc
4.48%Adage Capital Partners Gp LLC
4.45%
Corporate Announcements
Janux Therapeutics Inc Earnings
Janux Therapeutics Inc’s price-to-earnings ratio stands at None
Read More
Company Information
janux therapeutics is an innovative biopharmaceutical company developing next-generation therapeutics based on its proprietary tumor activated t cell engager (tractr) platform technology to better treat patients suffering from cancer. janux’s initial focus is on developing a novel class of t cell engagers (tces), and its lead product candidates are designed to target clinically validated drug targets. while tce therapeutics have displayed potent anti-tumor activity in hematological cancers, developing tces to treat solid tumors have faced challenges due to the limitations of prior tce technologies, namely (i) overactivation of the immune system leading to cytokine release syndrome, (ii) on-target, healthy tissue toxicities, and (iii) poor pharmacokinetics leading to short half-life. janux is using its tractr platform technology to engineer product candidates designed to overcome these limitations. janux is developing a broad pipeline with lead programs targeting prostate-specific membr
Organization | Janux Therapeutics Inc |
Employees | 76 |
CEO | Dr. David Alan Campbell Ph.D. |
Industry | Services |
